Cepheid Management to Present at the 7th Annual Needham Medical Technology and Biotechnology Conference and William Blair's 28th

SUNNYVALE, Calif., June 4 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) announced today that the Company will webcast presentations at the following investor conferences:

Andrew Miller, Senior Vice President, Chief Financial Officer, David Persing, Executive Vice President, Chief Medical and Technology Officer, and Rob Koska, Senior Vice President, Worldwide Commercial Operations, will provide a corporate overview at each of the conferences.

In the webcast presentations, Cepheid will provide an update on its test pipeline strategy through fiscal 2013.

Live webcasts, along with accompanying presentation slides, may be accessed on Cepheid's Web site at http://www.cepheid.com under Investors: Events: Webcasts and Presentations. A replay of the webcast presentations will be available for 90 days following the live events. The updated investor presentation is now available for viewing on Cepheid's Web site under Investors.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, California, is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080129/LATU101LOGO)

SOURCE Cepheid